Open Access Article
This Open Access Article is licensed under a Creative Commons Attribution 3.0 Unported Licence
Correction: Synthesis and characterization of TPGS–gemcitabine prodrug micelles for pancreatic cancer therapy
Vaibhav Khareab,
Wejdan Al. Sakarchia,
Prem N. Guptab,
Anthony D. M. Curtisa and
Clare Hoskins*a
aInstitute of Science and Technology in Medicine, Keele University, Keele, Staffordshire ST55BJ, UK. E-mail: c.hoskins@keele.ac.uk
bFormulation and Drug Delivery Division, CSIR-Indian Institute of Integrative Medicine, Canal Road, Jammu, India 180001
First published on 22nd February 2017
Abstract
Correction for ‘Synthesis and characterization of TPGS–gemcitabine prodrug micelles for pancreatic cancer therapy’ by Vaibhav Khare et al., RSC Adv., 2016, 6, 60126–60137.
Fig. 1 in the original manuscript incorrectly represented the structures of the TPGS–succinic acid (TPGS–SA) intermediate and the TPGS–Gem prodrug. The correct Fig. 1 image and caption are given below, along with additional explanatory text from the authors.
 | ||
| Fig. 1 A schematic representation of the reaction involved in the synthesis of tocopherol polyethylene glycol succinate 1000 (TPGS)–gemcitabine prodrug. | ||
According to the chemistry and methodology cited in Section 2.2 of the manuscript, reaction of TPGS with succinic anhydride in the presence of 4-(N,N-dimethylamino)pyridine (DMAP) gave TPGS–SA ester intermediate. Subsequent amide coupling reaction of TPGS–SA with gemcitabine in the presence of dicyclohexylcarbodiimide (DCC) (1 equivalent) and N-hydroxysuccinimide (NHS) (2 equivalents) gave the TPGS–Gem prodrug conjugate.
The Royal Society of Chemistry apologises for these errors and any consequent inconvenience to authors and readers.
| This journal is © The Royal Society of Chemistry 2017 |